Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response

Cancer Research

Volumn 62, Issue 6, 2000, Pages 1702-1706

  Griffin, Robert J ^a   Williams, Brent W ^a   Wild, Robert ^b   Cherrington, Julie M ^b   Park, Heonjoo ^a   Song, Chang W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR GROWTH; VASCULAR ENDOTHELIUM; X IRRADIATION;

ANIMALS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; FEMALE; FIBROSARCOMA; HUMANS; INDOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; PANCREATIC NEOPLASMS; PYRROLES; RADIATION-SENSITIZING AGENTS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0037085933     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
2. VEGF: An update on biological and therapeutic aspects
3. Tumor angiogenesis: Past, present and the near future
4. Angiogenesis in cancer and other diseases
5. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
6. VEGF receptor signaling in tumor angiogenesis
7. Signal transduction by fibroblast growth factor receptors
8. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
9. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis
10. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors
11. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
12. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes
13. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro
14. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
15. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
16. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
17. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIK-I/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
18. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
19. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
20. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
21. Antiangiogenic strategies and agents in clinical trials
22. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
23. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
24. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity
25. Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy
26. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
27. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
28. Anti-VEGF treatments augments tumor radiation response under normoxic or hypoxic conditions
29. 2and cell survival in tumors
30. SU6668, a broad spectrum angiogenesis inhibitor, is active in diverse models of tumor growth and metastasis
31. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
32. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival